286 related articles for article (PubMed ID: 17503348)
1. Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E; Hu XF; Xing PX
Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
[TBL] [Abstract][Full Text] [Related]
2. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
3. MUC1: a target molecule for cancer therapy.
Singh R; Bandyopadhyay D
Cancer Biol Ther; 2007 Apr; 6(4):481-6. PubMed ID: 18027437
[TBL] [Abstract][Full Text] [Related]
4. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
6. MUC1 and breast cancer.
Apostolopoulos V; Pietersz GA; McKenzie IF
Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
[TBL] [Abstract][Full Text] [Related]
7. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.
Van Elssen CH; Clausen H; Germeraad WT; Bennet EP; Menheere PP; Bos GM; Vanderlocht J
J Immunol Methods; 2011 Feb; 365(1-2):87-94. PubMed ID: 21194532
[TBL] [Abstract][Full Text] [Related]
9. Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells.
Fattorossi A; Battaglia A; Malinconico P; Stoler A; Andreocci L; Parente D; Coscarella A; Maggiano N; Perillo A; Pierelli L; Scambia G
Exp Cell Res; 2002 Oct; 280(1):107-18. PubMed ID: 12372344
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
Scholl SM; Balloul JM; Le Goc G; Bizouarne N; Schatz C; Kieny MP; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres B
J Immunother; 2000; 23(5):570-80. PubMed ID: 11001550
[TBL] [Abstract][Full Text] [Related]
11. [Vaccination against the tumoral mammary epithelial cells expressing MUC1 mucin].
Scholl SM; Pouillart P
Bull Cancer; 1997 Jan; 84(1):61-4. PubMed ID: 9180861
[TBL] [Abstract][Full Text] [Related]
12. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.
Pathangey LB; Lakshminarayanan V; Suman VJ; Pockaj BA; Mukherjee P; Gendler SJ
Biomolecules; 2016 Jun; 6(3):. PubMed ID: 27367740
[TBL] [Abstract][Full Text] [Related]
14. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.
Yang H; Cho NH; Seong SY
Clin Exp Immunol; 2009 Nov; 158(2):174-85. PubMed ID: 19737144
[TBL] [Abstract][Full Text] [Related]
15. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
[TBL] [Abstract][Full Text] [Related]
16. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
17. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.
Bäckström M; Link T; Olson FJ; Karlsson H; Graham R; Picco G; Burchell J; Taylor-Papadimitriou J; Noll T; Hansson GC
Biochem J; 2003 Dec; 376(Pt 3):677-86. PubMed ID: 12950230
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
[TBL] [Abstract][Full Text] [Related]
19. MUC1 and cancer.
Taylor-Papadimitriou J; Burchell J; Miles DW; Dalziel M
Biochim Biophys Acta; 1999 Oct; 1455(2-3):301-13. PubMed ID: 10571020
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
